Find a Clinical Trial

Showing 221 - 230 of 238 Trials

  • Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

    Principal Investigator:

    Joseph G. Jurcic, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05735184

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to determine the safe dose of ziftomenib to be used in combination with other drugs to treat acute myeloid leukemia. Another purpose is to determine how well ziftomenib works in combination with the other drugs for acute myeloid leukemia. Ziftomenib has not been approved by Food and Drug Administration (FDA). Ziftomenib is an experimental drug may help in preventing or slowing the leukemia cells from growing and dividing. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have life expectancy greater than 3 months - Must not be diagnosis...

  • R5458-ONC-2012:PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTICD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

    Principal Investigator:

    Rajshekar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05137054

    Population:

    Adult

    Phase:

    I
    This study is the first time REGN5458 will be combined with other cancer therapies. The main goal is to understand if REGN5458 can be given safely with other cancer study treatments, and if so, what dose of REGN5458 should be used for each combination. The investigational drug, REGN5458, is not approved by the Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Are you at least 18 years of age? - Are you likely to live for at least six more months? -Do you have measurable disease as defined in the protocol according to International Myeloma Working Group (IMWG)...

  • Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A PilotStudy

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06673329

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to...

  • A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04960787

    Population:

    Adult

    Phase:

    NA
    Studies have shown that cancer patients and their spouses may be at high risk for financial problems because of the cost of cancer treatment. This study is being done to answer the following question: Can a financial navigation program help patients and their spouses understand and better manage the financial aspects of cancer care? A financial navigator is a person or team who work with patients and their families to help them reduce stress or hardship related to the cost of cancer treatment. Financial navigators help patients understand their out-of-pocket expenses and what their health...

  • A phase IV study of Apricity C.A.R.E. program for Cancer Adverse events Rapid Evaluation to improve treatment outcomes of ethnic/racial minority non-small cell lung cancer (NSCLC) patients receiving immunotherapy

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05812274

    Population:

    Adult

    Phase:

    NA
    The therapy you are receiving for your cancer has known side effects. If those side effects are caught early, they may be less serious, easier to treat, and less likely to lead to discontinuation of your cancer therapy. Apricity Health has created the Apricity CARE program, which includes a smart phone app called ApricityCare for monitoring and reporting these side effects, and licensed nurses who can respond to you virtually to evaluate your side effects and communicate to your doctors without delay. The app also has education material to teach you about these side effects. You can also have...

  • A NON-RANDOMIZED PROSPECTIVE CLINICAL TRIAL COMPARING THE NON-INFERIORITY OF SALPINGECTOMY TO SALPINGO-OOPHORECTOMY TO REDUCE THE RISK OF OVARIAN CANCER AMONG BRCA1 CARRIERS [SOROCk]

    Principal Investigator:

    Jason D. Wright, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04251052

    Population:

    Adult

    Phase:

    NA
    The main purpose of this study is to determine if two surgical procedures, the usual approach of removing the fallopian tubes and ovaries and the other approach of removing the fallopian tubes at this time with the plan to remove the ovaries at a later time, are no different for ovarian cancer risk reduction in women with BRCA1 mutations who have completed childbearing. In this study, the removal of fallopian tubes will be compared to the removal of fallopian tubes and ovaries. The study will also examine what factors go into deciding which surgery to have and symptoms after surgery caused by...

  • DISRUPT: Aim 2

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05146297

    Population:

    Adult

    Phase:

    NA
    That Black, Indigenous, and People of Color (BIPOC) are more likely to die from their cancer is well known. Despite years of progress in cancer research and treatment, most research is done in white populations. For this reason, it is not certain how best to treat BIPOC with cancer. The number of people with cancer who join a clinical trial (CT) in the United States at 8%. This low number is due to many reasons including the things related to the healthcare system, the number and type of clinical trials that are available, and the other illnesses patients have. These factors affect BIPOC...

  • Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to Reduce Refills after Cancer-Related Surgery

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05585788

    Population:

    Adult

    Phase:

    NA
    - Are you of 18 years or older? - Do you have upcoming open, non-laparoscopic surgery? - Is it planned that you will receive opioids in the post-operative period? - Are you able to download and use a iPhone or iPad application? Are you Eligible? (Inclusion Criteria) Are you of 18 years or older? Do you have upcoming open, non-laparoscopic surgery? Is it planned that you will receive opioids in the post-operative period? Are you able to download and use a iPhone or iPad application?

  • Feasibility Study of Adaptive Radiotherapy for the Treatment of Locally-Advanced Anal Squamous Cell Carcinoma

    Principal Investigator:

    Lisa Ann Kachnic, MD, FASTRO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05838391

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to find out if performing adaptive planning during the treatment anal cancer will decrease the dose of radiation to normal organs and decrease the side effects. In this study, subjects will have a daily adjustment (adaptation) of their radiation plan as the tumor changes during the radiation treatment. The radiation will be given as part the standard of care treatment with chemotherapy, known as chemo-RT (CRT). Are you Eligible? (Inclusion Criteria) To be considered for this study, you must: 1. Have invasive anal cancer confirmed with biopsy 2. Be greater than 18...

  • IMPACT Trial: Intervention to iMProve AdherenCe equitably

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05496829

    Population:

    Adult

    Phase:

    NA
    Many patients with breast cancer, who also take medicine to prevent heart disease such as a blood pressure medicine or a cholesterol medicine, experience frustration with the large number and difficult scheduling of their medications, known as “pill burden”. This study will help us find out how much “pill burden” exists in subjects with cancer at various stages, and how this intervention can help. Results of this study may help us figure out the best way to help patients manage their medications in the future. Are you Eligible? (Inclusion Criteria) Are you diagnosed...

Pages